Baseline characteristics of patients who completed the Asthma Quality of Life Questionnaire(AQLQ)
| Characteristics | Stratum 1 | Stratum 2 | Stratum 3 | |||
| SFC | FP | SFC | FP | SFC | FP | |
| Patients n# (ITT population) | 291 (548) | 290 (550) | 351 (585) | 343 (578) | 359 (576) | 360 (579) |
| Age yrs (ITT population) | 37.3±14.8 (36.1) | 37.0±14.6 (36.4) | 40.8±16.1 (40.4) | 41.0±16.3 (40.3) | 42.4±16.0 (44.1) | 41.3±15.9 (42.7) |
| Female % (ITT population) | 59 (57) | 54 (57) | 57 (58) | 58 (60) | 58 (57) | 61 (59) |
| AQLQ score | ||||||
| Overall score | 4.4±1.01 | 4.5±1.00 | 4.7±1.07 | 4.5±1.03 | 4.5±1.05 | 4.5±1.05 |
| Activity limitation domain | 4.6±1.07 | 4.6±1.05 | 4.7±1.10 | 4.5±1.08 | 4.5±1.11 | 4.5±1.13 |
| Symptom domain | 4.2±1.10 | 4.4±1.07 | 4.6±1.11 | 4.5±1.10 | 4.5±1.09 | 4.5±1.09 |
| Emotional function domain | 4.4±1.36 | 4.6±1.42 | 4.8±1.47 | 4.6±1.37 | 4.6±1.44 | 4.7±1.45 |
| Environmental stimuli domain | 4.4±1.32 | 4.4±1.35 | 4.6±1.40 | 4.4± 1.38 | 4.4±1.41 | 4.4±1.45 |
Data are presented as mean±sd, unless otherwise stated. SFC: salmeterol/fluticasone propionate combination; FP: fluticasone propionate; ITT: intention to treat #: completing at least one AQLQ questionnaire at any time during the study.